Albany Molecular Research (AMRI) Tops Q2 EPS by 4c; Guides Q3 Contract Revs
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Price: $21.74 --0%
Financial Fact:
Total operating expenses: 168.4M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Total operating expenses: 168.4M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Albany Molecular Research (NASDAQ: AMRI) reported Q2 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $50 million versus the consensus estimate of $52 million.
Guides Q312 contract revenue to range from $43 million to $46 million. Affirms FY12 contract revs outlook.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Guides Q312 contract revenue to range from $43 million to $46 million. Affirms FY12 contract revs outlook.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
